130,564 Shares in 4D Molecular Therapeutics, Inc. $FDMT Acquired by Exome Asset Management LLC

Exome Asset Management LLC acquired a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 130,564 shares of the company’s stock, valued at approximately $1,216,000.

A number of other institutional investors and hedge funds have also bought and sold shares of FDMT. Wexford Capital LP purchased a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter worth $41,000. Daiwa Securities Group Inc. grew its position in shares of 4D Molecular Therapeutics by 3,362.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after buying an additional 6,186 shares in the last quarter. Susquehanna Portfolio Strategies LLC purchased a new position in shares of 4D Molecular Therapeutics during the fourth quarter valued at $77,000. Martingale Asset Management L P increased its stake in shares of 4D Molecular Therapeutics by 12.4% during the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock valued at $88,000 after buying an additional 1,303 shares during the period. Finally, Gabelli Funds LLC purchased a new position in shares of 4D Molecular Therapeutics during the fourth quarter valued at $90,000. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Trading Up 3.1%

Shares of NASDAQ:FDMT opened at $10.38 on Tuesday. The company has a market capitalization of $542.67 million, a PE ratio of -4.04 and a beta of 2.70. 4D Molecular Therapeutics, Inc. has a 12-month low of $4.27 and a 12-month high of $14.00. The business’s fifty day simple moving average is $10.47 and its 200-day simple moving average is $9.59.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The company had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. Research analysts predict that 4D Molecular Therapeutics, Inc. will post -3.8 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Jefferies Financial Group reissued a “buy” rating and set a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. The Goldman Sachs Group set a $33.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, May 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.88.

Insider Activity

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 9,810 shares of the stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the sale, the insider directly owned 8,617 shares of the company’s stock, valued at approximately $103,404. This represents a 53.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider David Kirn sold 114,746 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the completion of the sale, the insider owned 942,485 shares in the company, valued at $9,867,817.95. This represents a 10.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 184,811 shares of company stock worth $2,075,906 in the last quarter. 7.90% of the stock is owned by insiders.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.